Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib sequentially combined with MEC for relapsed or refractory FLT3-mutated acute myeloid leukemia
jRCTs041200067Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gilteritinib, mitoxantrone, etoposide and cytarabine in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Primary endpoint: Complete remission rate during treatment. Started Dec 2020; status: active, not recruiting.
02
Drugs
gilteritinibmitoxantroneetoposidecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs041200067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200067.